Wragge Lawrence Graham & Co’s Life Sciences team has advised GlaxoSmithKline (GSK) on the sale of its shareholding interests in biopharmaceutical company Convergence Pharmaceuticals to NASDAQ-listed Biogen Idec. The $675 million deal takes place just four years after the team advised GSK on the spin-out venture which created Convergence.
The deal sees Biogen Idec pay Convergence shareholders an upfront payment of $200 million for the business and its innovative portfolio of drugs for use in the treatment of neuropathic pain. These include products that have demonstrated ‘proof of concept’ for treating conditions such as sciatica and trigeminal neuralgia, which causes severe, episodic facial pain. Shareholders will also be eligible for future milestone payments of up to $475 million, contingent on future milestone events. More >>
Tags: Gowling WLG | London